Unknown PHASE2 INTERVENTIONAL 2-arm NCT02435186

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Sponsor: Shenzhen SiBiono GeneTech Co.,Ltd

Conditions Fallopian Tube Cancer Ovarian Epithelial Cancer Primary Peritoneal Cancer

Interventions Cisplatin Paclitaxel p53 gene

Updated 6 times since 2017 Last updated: Apr 30, 2015 Started: Jun 30, 2015 Primary completion: Aug 31, 2018 Completion: Aug 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02435186, this PHASE2 trial focuses on Fallopian Tube Cancer and Ovarian Epithelial Cancer and remains ongoing. Sponsored by Shenzhen SiBiono GeneTech Co.,Ltd, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Sep 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Sep 2018 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen SiBiono GeneTech Co.,Ltd

Data source: Shenzhen SiBiono GeneTech Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenyang, China